Profile data is unavailable for this security.
About the company
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
- Revenue in USD (TTM)153.73m
- Net income in USD-106.79m
- Incorporated2003
- Employees302.00
- LocationSutro Biopharma Inc111 Oyster Point Blvd.SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 392-8412
- Fax+1 (302) 655-5049
- Websitehttps://www.sutrobio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerus Corp | 186.80m | -37.49m | 299.52m | 288.00 | -- | 5.58 | -- | 1.60 | -0.2086 | -0.2086 | 1.04 | 0.2905 | 0.8984 | 2.03 | 5.34 | 648,600.70 | -18.11 | -25.99 | -32.81 | -40.62 | 62.54 | 61.90 | -20.15 | -35.81 | 1.55 | -2.91 | 0.5989 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| CytomX Therapeutics Inc | 101.21m | -569.00k | 300.05m | 120.00 | -- | -- | 186.83 | 2.96 | -0.0191 | -0.0191 | 1.37 | -0.7049 | 0.4375 | -- | 5.14 | 843,450.00 | -0.246 | -21.53 | -0.7382 | -32.32 | -- | -- | -0.5622 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Aquestive Therapeutics Inc | 50.58m | -7.87m | 301.87m | 135.00 | -- | -- | -- | 5.97 | -0.1437 | -0.1437 | 0.7691 | -1.55 | 0.8836 | 3.32 | 7.68 | 374,688.90 | -13.75 | -76.63 | -27.78 | -123.85 | 58.82 | 64.24 | -15.56 | -102.95 | 1.87 | -- | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 304.12m | 449.00 | -- | 6.84 | -- | 5.05 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| ESSA Pharma Inc | 0.00 | -25.80m | 304.36m | 50.00 | -- | 2.16 | -- | -- | -0.5851 | -0.5851 | 0.00 | 3.19 | 0.00 | -- | -- | 0.00 | -16.68 | -23.01 | -17.03 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Q32 Bio Inc | 1.16m | -112.96m | 305.28m | 7.00 | -- | 1.13 | -- | 264.08 | -35.17 | -35.17 | 0.3598 | 22.64 | 0.0074 | -- | -- | 165,142.90 | -55.64 | -34.98 | -62.45 | -37.92 | -- | -- | -7,532.87 | -971.76 | -- | -- | 0.00 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Inovio Pharmaceuticals Inc | 832.01k | -135.12m | 306.48m | 122.00 | -- | 2.35 | -- | 368.37 | -6.12 | -6.12 | 0.0375 | 5.15 | 0.0032 | -- | 0.9778 | 6,819.75 | -52.02 | -59.52 | -71.11 | -71.29 | -- | -- | -16,239.87 | -4,097.36 | -- | -- | 0.125 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Verrica Pharmaceuticals Inc | 5.12m | -67.00m | 307.97m | 100.00 | -- | 15.58 | -- | 60.10 | -1.46 | -1.46 | 0.113 | 0.466 | 0.0811 | -- | 2.09 | 51,240.00 | -106.07 | -55.75 | -126.60 | -78.33 | 85.44 | -- | -1,307.48 | -754.94 | 4.49 | -51.74 | 0.6914 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Fractyl Health Inc | 120.00k | -94.27m | 311.69m | 102.00 | -- | -- | -- | 2,597.40 | -1.97 | -1.97 | 0.0025 | -0.7881 | -- | -- | -- | 1,176.47 | -- | -- | -- | -- | 35.83 | -- | -64,242.50 | -- | 3.18 | -2.62 | 3.17 | -- | -- | -- | -48.15 | -- | -- | -- |
| Sutro Biopharma Inc | 153.73m | -106.79m | 313.16m | 302.00 | -- | 1.56 | -- | 2.04 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Anavex Life Sciences Corp | 0.00 | -43.16m | 316.13m | 40.00 | -- | 2.33 | -- | -- | -0.5357 | -0.5357 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -29.12 | -40.04 | -31.88 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Procaps Group SA | 414.10m | 52.20m | 318.16m | 5.50k | 5.41 | 8.08 | 4.57 | 0.7683 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Enanta Pharmaceuticals Inc | 73.62m | -138.24m | 320.94m | 145.00 | -- | 1.67 | -- | 4.36 | -6.56 | -6.56 | 3.50 | 9.07 | 0.1897 | -- | 4.79 | 507,737.90 | -35.63 | -14.56 | -40.03 | -15.62 | -- | -- | -187.77 | -54.96 | -- | -- | 0.0074 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| CorMedix Inc | 0.00 | -46.34m | 321.09m | 82.00 | -- | 4.57 | -- | -- | -0.9172 | -0.9172 | 0.00 | 1.28 | 0.00 | 0.00 | -- | 0.00 | -64.32 | -54.84 | -73.33 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.78 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| MeiraGTx Holdings PLC | 14.02m | -84.03m | 321.53m | 419.00 | -- | 2.30 | -- | 22.94 | -1.58 | -1.58 | 0.2483 | 2.17 | 0.0435 | -- | 0.8908 | 33,453.46 | -26.06 | -26.40 | -33.89 | -32.66 | -- | -- | -599.47 | -420.70 | -- | -91.62 | 0.3429 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Organogenesis Holdings Inc | 433.14m | 4.95m | 328.59m | 862.00 | 67.74 | 1.17 | 16.18 | 0.7586 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
Data as of May 06 2024. Currency figures normalised to Sutro Biopharma Inc's reporting currency: US Dollar USD
61.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Point72 Asset Management LPas of 04 Apr 2024 | 5.93m | 9.50% |
| Suvretta Capital Management LLCas of 31 Dec 2023 | 5.78m | 9.25% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.63m | 7.41% |
| Adage Capital Management LPas of 31 Dec 2023 | 4.47m | 7.16% |
| Millennium Management LLCas of 10 Jan 2024 | 3.45m | 5.53% |
| BVF Partners LPas of 31 Dec 2023 | 3.35m | 5.36% |
| Rubric Capital Management LPas of 31 Dec 2023 | 3.34m | 5.36% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.84m | 4.55% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 2.74m | 4.39% |
| Kynam Capital Management LPas of 31 Dec 2023 | 2.00m | 3.21% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
